Replay our online event “Rethink high content screening workflows for smarter decisions.“
What if an end-to-end phenotypic solution could help direct the decision-making process in drug screening?
90% of drugs are still failing in clinical trials, with 75-80% of these failures caused by efficacy or safety issues. Focusing solely on target-based drug discovery can miss the wider context of drug effects, and current methods are not sufficient for ensuring safety and toxicity.
At Nanolive, our goal is to de-risk the in vitro phase of drug development by shifting the focus from isolated targets to comprehensive cellular analysis to increase confidence in lead candidates. We do this by simplifying and streamlining workflows with an end-to-end AI-powered solution that acquires, integrates and analyzes high-content cell data in a single place for in-depth insights into every drug candidate.
Get a look into Nanolive’s high content screening workflow in this on-demand Online Demo, as our Field Application Specialist Matthias Schade guides us through the insights gained from a high-content phenotypic screen.
Watch the recording to discover:
- More insights into drug mechanism of action and side effects
- More biologically relevant conclusions
- Dynamic, real-time data, to move beyond the limits of endpoint assays
- Noninvasive monitoring of sensitive cells to preserve their natural behavior
This recorded online event is ideal for biopharma professionals who are looking to:
- Increase reproducibility with scalable, automated analysis
- Accelerate drug screening and candidate selection with high-content data
- Reduce decision fatigue at the planning level
- Reduce data silos and complex integration and analysis
- Support more informed, unbiased decision-making with label-free data
Read our latest news
Seminar – Label-Free Live Cell Analysis: Applications in Cancer Cell Death and Immune Engineering
Measuring CAR T potency with label-free imaging
